NovaBay Pharmaceuticals is a clinical stage company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections. The company’s Aganocide compounds mimic the body’s immune system, acting rapidly and effectively to defeat multi-drug resistant pathogens without causing resistance. NovaBay’s lead Aganocide compound is in Phase 2 clinical testing for treating Pink Eye, Impetigo and Catheter-Associated Urinary Tract Infection. The company has significant corporate partnerships with Alcon, the world’s leading ophthalmology company, and Galderma S.A., a global pharmaceutical firm dedicated to dermatology. NovaBay has also retained proprietary early stage programs addressing large markets such as onychomychosis, or nail fungus, and common cold.
VN:F [1.9.7_1111]
Rating: 3.7/5 (3 votes cast)
VN:F [1.9.7_1111]
NovaBay Pharmaceuticals, Inc., 3.7 out of 5 based on 3 ratings